Top

Published in:

Open Access 01-12-2015 | Research

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Authors: Dominika J Maskus, Susanne Bethke, Melanie Seidel, Stephanie Kapelski, Otchere Addai-Mensah, Alexander Boes, Güven Edgü, Holger Spiegel, Andreas Reimann, Rainer Fischer, Stefan Barth, Torsten Klockenbring, Rolf Fendel

Published in: Malaria Journal | Issue 1/2015

Abstract

Background

Semi-immunity against the malaria parasite is defined by a protection against clinical episodes of malaria and is partially mediated by a repertoire of inhibitory antibodies directed against the blood stage of Plasmodium falciparum, in particular against surface proteins of merozoites, the invasive form of the parasite. Such antibodies may be used for preventive or therapeutic treatment of P. falciparum malaria. Here, the isolation and characterization of novel human monoclonal antibodies (humAbs) for such applications is described.

Methods

B lymphocytes had been selected by flow cytometry for specificity against merozoite surface proteins, including the merozoite surface protein 10 (MSP10). After Epstein-Barr virus (EBV) transformation and identification of promising resulting lymphoblastoid cell lines (LCLs), human immunoglobulin heavy and light chain variable regions (Vh or Vl regions) were secured, cloned into plant expression vectors and transiently produced in Nicotiana benthamiana in the context of human full-size IgG1:κ. The specificity and the affinity of the generated antibodies were assessed by ELISA, dotblot and surface plasmon resonance (SPR) spectroscopy. The growth inhibitory activity was evaluated based on growth inhibition assays (GIAs) using the parasite strain 3D7A.

Results

Supernatants from two LCLs, 5E8 and 5F6, showed reactivity against the second (5E8) or first (5F6) epidermal growth factor (EGF)-like domain of MSP10. The isolated V regions were recombinantly expressed in their natural pairing as well as in combination with each other. The resulting recombinant humAbs showed affinities of 9.27 × 10⁻⁷ M [humAb10.1 (H5F6:κ5E8)], 5.46 × 10⁻⁹ M [humAb10.2 (H5F6:κ5F6)] and 4.34 × 10⁻⁹ M [humAb10.3 (H5E8:κ5E8)]. In GIAs, these antibodies exhibited EC₅₀ values of 4.1 mg/ml [95% confidence interval (CI) 2.6–6.6 mg/ml], 6.9 mg/ml (CI 5.5–8.6 mg/ml) and 9.5 mg/ml (CI 5.5–16.4 mg/ml), respectively.

Conclusion

This report describes a platform for the isolation of human antibodies from semi-immune blood donors by EBV transformation and their subsequent characterization after transient expression in plants. To our knowledge, the presented antibodies are the first humAbs directed against P. falciparum MSP10 to be described. They recognize the EGF-like folds of MSP10 and bind these with high affinity. Moreover, these antibodies inhibit P. falciparum 3D7A growth in vitro.

WHO (2014) World Malaria Report 2014. World Health Organization, Geneva

Ramasamy R (1998) Molecular basis for evasion of host immunity and pathogenesis in malaria. Biochim Biophys Acta 1406:10–27PubMedCrossRef

Langhorne J, Ndungu FM, Sponaas A, Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9:725–732. doi:10.1038/ni.f.205 PubMedCrossRef

Dzikowski R, Deitsch KW (2009) Genetics of antigenic variation in Plasmodium falciparum. Curr Genet 55:103–110. doi:10.1007/s00294-009-0233-2 PubMedCentralPubMedCrossRef

Costa G, Loizon S, Guenot M, Mocan I, Halary F, de Saint-Basile G et al (2011) Control of Plasmodium falciparum erythrocytic cycle: γδ T cells target the red blood cell-invasive merozoites. Blood 118:6952–6962. doi:10.1182/blood-2011-08-376111 PubMedCrossRef

Baird JK (1995) Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today 11:105–111PubMedCrossRef

Chelimo K, Ofulla AV, Narum DL, Kazura JW, Lanar DE, John CC (2005) Antibodies to Plasmodium falciparum antigens vary by age and antigen in children in a malaria-holoendemic area of Kenya. Pediatr Infect Dis J 24:680–684PubMedCrossRef

Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh et al (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76:2240–2248. doi:10.1128/IAI.01585-07 PubMedCentralPubMedCrossRef

Cohen S, McGregor IA, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192:733–737PubMedCrossRef

10.

Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P et al (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45:297–308PubMed

11.

Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172:379–382PubMedCrossRef

12.

Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182:409–418PubMedCrossRef

13.

Kapelski S, Klockenbring T, Fischer R, Barth S, Fendel R (2014) Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J Leukoc Biol 96:1131–1142. doi:10.1189/jlb.4A0614-283RR PubMedCrossRef

14.

Roestenberg M, McCall M, Hopman J, Wiersma J, Luty, Adrian JF et al (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361:468–477. doi:10.1056/NEJMoa0805832 PubMedCrossRef

15.

Doolan DL (2011) Plasmodium immunomics. Int J Parasitol 41:3–20. doi:10.1016/j.ijpara.2010.08.002 PubMedCentralPubMedCrossRef

16.

Richards JS, Beeson JG (2009) The future for blood-stage vaccines against malaria. Immunol Cell Biol 87:377–390. doi:10.1038/icb.2009.27 PubMedCrossRef

17.

Black CG, Wang L, Wu T, Coppel RL (2003) Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum. Mol Biochem Parasitol 127:59–68PubMedCrossRef

18.

Puentes A, Ocampo M, Rodriguez LE, Vera R, Valbuena J, Curtidor H et al (2005) Identifying Plasmodium falciparum merozoite surface protein-10 human erythrocyte specific binding regions. Biochimie 87:461–472. doi:10.1016/j.biochi.2005.01.001 PubMedCrossRef

19.

Voepel N, Boes A, Edgue G, Beiss V, Kapelski S, Reimann A et al (2014) Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants. Biotechnol J 9:1435–1445. doi:10.1002/biot.201400350 PubMedCrossRef

20.

Mordmüller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C et al (2010) Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene Gabon. Vaccine 28:6698–6703. doi:10.1016/j.vaccine.2010.07.085 PubMedCentralPubMedCrossRef

21.

Team RC (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing. European Environment Agency, Copenhagen, Denmark, Vienna

22.

Fraussen J, Vrolix K, Martinez-Martinez P, Losen M, Meulemans E, De Baets MH et al (2010) A novel method for making human monoclonal antibodies. J Autoimmun 35:130–134. doi:10.1016/j.jaut.2010.05.001 PubMedCrossRef

23.

Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329:112–124. doi:10.1016/j.jim.2007.09.017 PubMedCentralPubMedCrossRef

24.

Brochet X, Lefranc M, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36:W503–W508. doi:10.1093/nar/gkn316 PubMedCentralPubMedCrossRef

25.

Stothard P (2000) The sequence manipulation suite: javaScript programs for analyzing and formatting protein and DNA sequences. Biotechniques 28(1102):1104

26.

Martin ACR (2001) Protein sequence and structure analysis of antibody variable domains. In: Kontermann R, Dübel S (eds) Antibody Engineering. Springer, Heidelberg, pp 33–51. doi:10.1007/978-3-642-01147-4_3

27.

Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. doi:10.1038/msb.2011.75 PubMedCentralPubMedCrossRef

28.

Monigatti F, Gasteiger E, Bairoch A, Jung E (2002) The Sulfinator: predicting tyrosine sulfation sites in protein sequences. Bioinformatics 18:769–770PubMedCrossRef

29.

Kapelski S, Boes A, Spiegel H, de Almeida M, Klockenbring T, Reimann A et al (2015) Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a Pf MSP4-specific antibody. Malar J 14:50. doi:10.1186/s12936-015-0577-7 PubMedCentralPubMedCrossRef

30.

Feller T, Thom P, Koch N, Spiegel H, Addai-Mensah O, Fischer R et al (2013) Plant-based production of recombinant Plasmodium surface protein pf38 and evaluation of its potential as a vaccine candidate. PLoS One 8:e79920. doi:10.1371/journal.pone.0079920 PubMedCentralPubMedCrossRef

31.

Trager W, Jensen JB (1976) Human malaria parasites in continuous culture. Science 193:673–675PubMedCrossRef

32.

Remarque EJ, Faber BW, Kocken, Clemens HM, Thomas AW (2008) A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 76:2660–2670. doi:10.1128/IAI.00170-08 PubMedCentralPubMedCrossRef

33.

Faber BW, Younis S, Remarque EJ, Rodriguez Garcia R, Riasat V, Walraven V et al (2013) Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun 81:1479–1490. doi:10.1128/IAI.01267-12 PubMedCentralPubMedCrossRef

34.

Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S et al (2013) Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One 8:e58724. doi:10.1371/journal.pone.0058724 PubMedCentralPubMedCrossRef

35.

Radfar A, Mendez D, Moneriz C, Linares M, Marin-Garcia P, Puyet A et al (2009) Synchronous culture of Plasmodium falciparum at high parasitemia levels. Nat Protoc 4:1899–1915. doi:10.1038/nprot.2009.198 PubMedCrossRef

36.

Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A et al (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70:6948–6960PubMedCentralPubMedCrossRef

37.

Beiss V, Spiegel H, Boes A, Kapelski S, Scheuermayer M, Edgue G et al (2015) Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein. Biotechnol Bioeng. doi:10.1002/bit.25548 PubMed

38.

Boes A, Spiegel H, Edgue G, Kapelski S, Scheuermayer M, Fendel R et al (2015) Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits. Plant Biotechnol J 13:222–234. doi:10.1111/pbi.12255 PubMedCrossRef

39.

Spiegel H, Schinkel H, Kastilan R, Dahm P, Boes A, Scheuermayer M et al (2014) Optimization of a multi-stage, multi-subunit malaria vaccine candidate for the production in Pichia pastoris by the identification and removal of protease cleavage sites. Biotechnol Bioeng. doi:10.1002/bit.25481 PubMed

40.

Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA et al (1995) Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 63:456–466PubMedCentralPubMed

41.

Wang L, Black CG, Marshall VM, Coppel RL (1999) Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect Immun 67:2193–2200PubMedCentralPubMed

42.

Moore KL (2009) Protein tyrosine sulfation: a critical posttranslation modification in plants and animals. Proc Natl Acad Sci USA 106:14741–14742. doi:10.1073/pnas.0908376106 PubMedCentralPubMedCrossRef

43.

Cheng X, Hayasaka H, Watanabe K, Tao Y, Liu J, Tsukamoto H et al (2007) Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum. Infect Immun 75:3614–3620. doi:10.1128/IAI.00062-07 PubMedCentralPubMedCrossRef

44.

Stubbs J, Olugbile S, Saidou B, Simpore J, Corradin G, Lanzavecchia A (2011) Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies. Infect Immun 79:1143–1152. doi:10.1128/IAI.01034-10 PubMedCentralPubMedCrossRef

45.

Lundquist R, Nielsen LK, Jafarshad A, Soesoe D, Christensen LH, Druilhe P et al (2006) Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun 74:3222–3231. doi:10.1128/IAI.00928-05 PubMedCentralPubMedCrossRef

46.

Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE et al (2013) Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med 210:389–399. doi:10.1084/jem.20121970 PubMedCentralPubMedCrossRef

47.

Barfod L, Bernasconi NL, Dahlback M, Jarrossay D, Andersen PH, Salanti A et al (2007) Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol 63:335–347. doi:10.1111/j.1365-2958.2006.05503.x PubMedCentralPubMedCrossRef

48.

Udomsangpetch R, Lundgren K, Berzins K, Wahlin B, Perlmann H, Troye-Blomberg M et al (1986) Human monoclonal antibodies to Pf 155, a major antigen of malaria parasite Plasmodium falciparum. Science 231:57–59PubMedCrossRef

49.

Kim S, Hwang S, Lee Y, Choi I, Park S, Kho W (2007) Single-chain antibody fragment specific for Plasmodium vivax Duffy binding protein. Clin Vaccine Immunol 14:726–731. doi:10.1128/CVI.00456-06 PubMedCentralPubMedCrossRef

50.

Roeffen WF, Raats JM, Teelen K, Hoet RM, Eling WM, van Venrooij WJ et al (2001) Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum. J Biol Chem 276:19807–19811. doi:10.1074/jbc.M100562200 PubMedCrossRef

51.

Chappel JA, Rogers WO, Hoffman SL, Kang AS (2004) Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J 3:28. doi:10.1186/1475-2875-3-28 PubMedCentralPubMedCrossRef

52.

Glasky MS, Reading CL (1989) Stability of specific immunoglobulin secretion by EBV-transformed lymphoblastoid cells and human-murine heterohybridomas. Hybridoma 8:377–389PubMedCrossRef

53.

Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L et al (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 6:392–402. doi:10.1111/j.1467-7652.2008.00330.x PubMedCrossRef

54.

Both L, van Dolleweerd C, Wright E, Banyard AC, Bulmer-Thomas B, Selden D et al (2013) Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB J. 27:2055–2065. doi:10.1096/fj.12-219964 PubMedCentralPubMedCrossRef

55.

Taylor RR, Egan A, McGuinness D, Jepson A, Adair R, Drakely C et al (1996) Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol 8:905–915PubMedCrossRef

56.

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ et al (2014) Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:55–62. doi:10.1038/nature13036 PubMedCentralPubMedCrossRef

57.

Robin G, Sato Y, Desplancq D, Rochel N, Weiss E, Martineau P (2014) Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody-antigen complexes. J Mol Biol 426:3729–3743. doi:10.1016/j.jmb.2014.08.013 PubMedCrossRef

58.

Tetteh, Kevin KA, Stewart LB, Ochola LI, Amambua-Ngwa A, Thomas AW, Marsh K et al (2009) Prospective identification of malaria parasite genes under balancing selection. PLoS One 4:5568. doi:10.1371/journal.pone.0005568 CrossRef

59.

Pacheco MA, Elango AP, Rahman AA, Fisher D, Collins WE, Barnwell JW et al (2012) Evidence of purifying selection on merozoite surface protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp.. Infect Genet Evol 12:978–986. doi:10.1016/j.meegid.2012.02.009 PubMedCentralPubMedCrossRef

60.

Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH et al (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16:963–968. doi:10.1128/CVI.00042-09 PubMedCentralPubMedCrossRef

61.

Douglas AD, Williams AR, Knuepfer E, Illingworth JJ, Furze JM, Crosnier C et al (2014) Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J Immunol 192:245–258. doi:10.4049/jimmunol.1302045 PubMedCrossRef

62.

Guevara JA, Holder AA, McBride JS, Blackman MJ (1997) Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186:1689–1699CrossRef

63.

Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H et al (2015) Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 42:580–590. doi:10.1016/j.immuni.2015.02.012 PubMedCentralPubMedCrossRef

64.

Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S et al (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2:e344. doi:10.1371/journal.pmed.0020344 PubMedCentralPubMedCrossRef

65.

Blackman MJ, Ling IT, Nicholls SC, Holder AA (1991) Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 49:29–33PubMedCrossRef

66.

Boyle MJ, Langer C, Chan J, Hodder AN, Coppel RL, Anders RF et al (2014) Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum. Infect Immun 82:924–936. doi:10.1128/IAI.00866-13 PubMedCentralPubMedCrossRef

67.

Bergmann-Leitner ES, Duncan EH, Angov E (2009) MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum. Malar J 8:183. doi:10.1186/1475-2875-8-183 PubMedCentralPubMedCrossRef

68.

Moss DK, Remarque EJ, Faber BW, Cavanagh DR, Arnot DE, Thomas AW et al (2012) Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development. Infect Immun 80:1280–1287. doi:10.1128/IAI.05887-11 PubMedCentralPubMedCrossRef

69.

Kapelski S, de Almeida M, Fischer R, Barth S, Fendel R (2015) Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain fv fusion protein. Antimicrob Agents Chemother 59:669–672. doi:10.1128/AAC.04190-14 PubMedCentralPubMedCrossRef

Title: Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10
Authors: Dominika J Maskus
Susanne Bethke
Melanie Seidel
Stephanie Kapelski
Otchere Addai-Mensah
Alexander Boes
Güven Edgü
Holger Spiegel
Andreas Reimann
Rainer Fischer
Stefan Barth
Torsten Klockenbring
Rolf Fendel
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/s12936-015-0797-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

The impact of livestock on the abundance, resting behaviour and sporozoite rate of malaria vectors in southern Tanzania

Measuring windows of selection for anti-malarial drug treatments

Prevalence of new and known species of haemoparasites in feral pigeons in northwest Italy

Association between anthropometry-based nutritional status and malaria: a systematic review of observational studies

Vivax malaria and chloroquine resistance: a neglected disease as an emerging threat

In vivo antiplasmodial and toxicological effect of Maytenus senegalensis traditionally used in the treatment of malaria in Tanzania

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page